Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (neutrophils) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 253 | 0.85 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2998
Sealed predictions
- PROK2 in dopamine neurons, braak+0.43 (p 0.244) → +0.07 (p 0.855)receipt 3004
Swarm cases
receipt 3004: PROK2 in dopamine neurons, braak
- power
- full sample +0.22 (p 0.389, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.22 (p 0.389, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.35 (p 0.150, n 18). could be the mix.
- skeptic
- leave-one-out range +0.11 to +0.36, sign flips 0; without severely affected donors +0.22 (p 0.389, n 18). fragile.
- cell type
- strongest in astrocytes: +0.59 (p 0.0092, n 18) vs +0.22 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PROK2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PROK2 · astrocytes · braak: substantia nigra, an independent cohort: not measured
Receipts
loading the receipts